Skip to main content
. Author manuscript; available in PMC: 2024 Feb 13.
Published in final edited form as: Neuropharmacology. 2020 Jul 29;177:108253. doi: 10.1016/j.neuropharm.2020.108253

Figure 2. CFA-induced LS, effect of RP67580 on NTX-induced allodynia.

Figure 2.

Paw withdrawal thresholds (PWT, von Frey) were measured in the ipsilateral (‘ipsi’) and contralateral (‘contra’) hindpaws. A, D: CFA (50 μl) was in injected in the hindpaw of eight rats at the time indicated by the arrow. B, E: On day 28, 10 μl of vehicle (0.3% DMSO in saline, B) or RP67580 (0.3 nmol in 0.3% DMSO, E) were injected i.th.; NTX (2.6 nmol in 10 μl i.th.) was injected 15 min later (arrow). The following two days, vehicle or RP67580 were injected daily. C, F: On day 35, NTX (2.6 nmol in 10 μl i.th.) was injected again (arrow). Each panel was analyzed by RM (both variables) 2-way ANOVA; overall p values for ‘time’ (effect of CFA or NTX) are given in each panel. Holm-Sidak’s post-hoc tests comparing to day −4 or 0 min: * p<0.05, ** p<0.01, *** p<0.001.